mv-012-968
Vaccineexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2020 (NCT04227210)
Timeline
Indications
Mechanism of action
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04909021 | Phase 1 | Jun 3, 2021 | Meissa Vaccines, Inc. |
| NCT04690335 | Phase 2 | Dec 29, 2020 | hVIVO Services Limited, Meissa Vaccines, Inc. |
| NCT04444284 | Phase 1 | Jun 9, 2020 | Meissa Vaccines, Inc. |
| NCT04227210 | Phase 1 | Jan 31, 2020 | Meissa Vaccines, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Meissa Vaccines, Inc. | For profit | 4 | 4 | 2 | 2020 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1